Strategic partnerships Aspeya engages in collaborations with large players such as Atlantic Grupa and is owned by a major industry player, suggesting opportunities for co-development, contract manufacturing, or distribution partnerships in wellness and inhaled therapeutics.

Inhaled therapeutics Active focus on inhaled formulations including ASY202; potential sales opportunities in contract development, clinical trial support, regulatory consulting, and eventual commercialization services for inhaled drug products.

Cannabinoids focus Structured emphasis on cannabinoids alongside traditional wellness products indicates demand for specialized cannabinoid formulation expertise, sourcing, quality systems, and regulatory navigation services.

Mid-market scale Headcount and revenue position suggest mid-sized manufacturing capabilities ripe for partnerships in private-label, toll manufacturing, and rapid-scale wellness product lines for regional or global distribution.

Tech and data enablement Adoption of analytics and cloud/ERP-like tools (SQL, MySQL, Tableau, Azure) implies opportunities to offer data-driven supply chain optimization, serialization, quality analytics, and digital marketing measurement services.